PDS Biotechnology Prioritizes Development of PDS0101 in Advanced Cancers Following Promising Phase 1 Clinical Outcome Data

NEXT STORY
Sabin Vaccine Institute Receives $20.5 Million From BARDA With Potential of up to $128 Million to Develop Ebola Sudan and Marburg Vaccines
PREV STORY
BioDelivery Sciences Announces Significant Additional Insurance Coverage for both BELBUCA® and Symproic®
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Sublimity Therapeutics Receives Investigational New Drug (IND) Clearance from U.S. Food and Drug Administration (FDA)

Company also Receives Ireland Authorization and Health Canada Clearance Phase 2b Clinical Trial of ...

author_avatar
NASDAQ Market News

BioNTech Publishes Data from mRNA-based BNT111 FixVac Melanoma Trial in Nature

author_avatar
NASDAQ Market News

FDA approves cobas Babesia, Roche’s first whole blood test for donor screening

author_avatar
NASDAQ Market News